Share ownership NovoCure Limited

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-13 pm EST			5-day change	1st Jan Change
13.65 ^USD	-3.74%		-4.48%	+5.57%

Jan. 12	NovoCure Reports Rise in Q4 Preliminary Revenue	MT
Dec. 01	Novocure Limited Announces CEO Changes	CI

Share class: NovoCure Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	108,201,434	98,185,526 ( 90.74 %)	0	90.74 %

Major shareholders: NovoCure Limited

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 15.04 %	16,769,878	15.04 %	217 M $
BlackRock Advisors LLC 10.67 %	11,892,851	10.67 %	154 M $
Vanguard Fiduciary Trust Co. 9.379 %	10,455,841	9.379 %	135 M $
Soleus Capital Management LP 8.651 %	9,644,872	8.651 %	125 M $
Hansjörg Wyss 7.303 %	8,141,397	7.303 %	105 M $
STATE STREET CORPORATION 2.342 %	2,610,688	2.342 %	34 M $
Geode Capital Management LLC 2.22 %	2,474,988	2.22 %	32 M $
Capital Research & Management Co. (World Investors) 1.794 %	2,000,000	1.794 %	26 M $
Teachers Advisors LLC 1.532 %	1,707,842	1.532 %	22 M $
Quantinno Capital Management LP 1.365 %	1,522,168	1.365 %	20 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	75.68%
Individuals	10.33%
Other	4.45%
State Street Corp.	2.34%
Silvercrest Asset Management Group, Inc.	0.63%
Schweizerische Nationalbank	0.18%
Manulife Financial Corp.	0.04%
SEI Investments Co.	0.02%
Unknown	6.33%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	72.67%
Individuals	10.33%
United Kingdom	5.64%
Ireland	1.5%
Denmark	0.87%
Canada	0.74%
Sweden	0.59%
Australia	0.47%
France	0.38%
Switzerland	0.24%
Puerto Rico	0.16%
China	0.02%
Cayman Islands	0.02%
Norway	0.02%
Singapore	0.01%
Hong Kong	0.01%

Based on 1000 largest holdings

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Employees

1,488

Sector

Medical Equipment, Supplies & Distribution

Calendar

12:45pm - J.P. Morgan Healthcare Conference

More about the company